Hiroshi Kitamura1, Atsushi Takahashi2, Fumiyasu Takei3, Hiroshi Hotta4, Noriomi Miyao5, Tetsuya Shindo6, Manabu Igarashi7, Hitoshi Tachiki8, Yasuharu Kunishima9, Takashi Muranaka10, Masanori Shigyo11, Yoshinori Ikehata12, Naoya Masumori13. 1. Univerity of Toyama, Toyama, Japan hkitamur@med.u-toyama.ac.jp. 2. Hakodate Goryoukaku Hospital, Hakodate, Japan. 3. Sunagawa City Medical Center, Sunagawa, Japan. 4. Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan. 5. Muroran City General Hospital, Muroran, Japan. 6. NTT East Japan Sapporo Hospital, Sapporo, Japan. 7. Takikawa Municipal Hospital, Takikawa, Japan. 8. Steel Memorial Muroran Hospital, Muroran, Japan. 9. Obihiro Kyokai Hospital, Obihiro, Japan. 10. JCHO Hokkaido Hospital, Sapporo, Japan. 11. Kushiro Red Cross Hospital, Kushiro, Japan. 12. Oji General Hospital, Tomakomai, Japan. 13. Sapporo Medical University School of Medicine, Sapporo, Japan.
Abstract
AIM: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted-therapy era. PATIENTS AND METHODS: We conducted a retrospective multi-institutional review of the medical records of 149 RCC patients with bone metastasis. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS. RESULTS: The median OS was 13.4 months. In multivariate analysis, molecular-targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone-modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular-targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy. CONCLUSION: Molecular-targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCC patients with metastasis in the bones. Copyright
AIM: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted-therapy era. PATIENTS AND METHODS: We conducted a retrospective multi-institutional review of the medical records of 149 RCCpatients with bone metastasis. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS. RESULTS: The median OS was 13.4 months. In multivariate analysis, molecular-targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone-modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular-targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy. CONCLUSION: Molecular-targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCCpatients with metastasis in the bones. Copyright